-
Eli Lilly’s Donanemab Receives Tacit Approval for Alzheimer’s Clinical Trial in China
•
The Center for Drug Evaluation (CDE) website indicates that US major Eli Lilly’s (NYSE: LLY) donanemab has obtained tacit clinical trial approval for assessment in treating early symptomatic Alzheimer’s disease (AD), including mild cognitive impairment due to AD, and mild AD. This approval marks a significant step forward in the…
-
Hainan Lecheng Partners with Fosun Pharma on Innovative Medical Devices and Diagnostics
•
The Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration has formed a partnership with Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) to translate scientific research achievements into commercial products. This collaboration aims to advance the development and commercialization of innovative medical technologies. Collaboration Focus AreasThe partnership…
-
Recbio’s R520A mRNA COVID-19 Vaccine Receives Clinical Approval in the Philippines
•
China-based Jiangsu Recbio Technology Co., Ltd has announced receiving clinical trial approval from the Food and Drug Administration of the Philippines for its mRNA COVID-19 vaccine R520A. This approval marks a significant milestone in the global rollout of Recbio’s innovative vaccine targeting the Omicron variant. Vaccine InnovationR520A, developed by Wuhan…
-
Pfizer’s Besponsa First Prescribed in China for Leukemia Treatment
•
US major Pfizer (NYSE: PFE) has announced the first prescriptions for its leukemia therapy Besponsa (inotuzumab ozogamicin) in multiple cities in China. This marks the official application of the world’s first antibody drug conjugate (ADC) in relapsed or refractory precursor B-cell ALL (R/R B-ALL). Mechanism of ActionBesponsa targets CD22, which…
-
Kelun Pharmaceutical Receives USD 30 Million from MSD for Licensing Deal
•
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced receiving USD 30 million from US major Merck Sharp & Dohme (MSD), triggered by a licensing agreement reached on May 16, 2022. This payment is part of a broader collaboration between the two companies to develop and commercialize an innovative…
-
ImmuneOnco Biopharmaceuticals Files for HKSE IPO with Comprehensive Tumor Immunotherapy Pipeline
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has submitted an initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE). The tumor immunotherapy-focused biotech company boasts a comprehensive product pipeline of over 10 drug candidates targeting innate and adaptive immune checkpoints. Five candidates are currently the focus of seven separate…
-
Clover Biopharmaceuticals’ SCB-2019 COVID-19 Vaccine Shows Strong Immune Response in Third Shot Study
•
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has published clinical data for its COVID-19 vaccine candidate SCB-2019 (CpG 1018/Alum) as a third shot. The double-blind, randomized, controlled study demonstrated significant increases in neutralizing antibodies against Omicron variants BA.2 and BA.1. Clinical Study ResultsThe study enrolled 3,755 subjects in Brazil, the Philippines,…
-
Harbour BioMed Receives FDA Approval for HBM7008 Clinical Trials
•
China-based Harbour BioMed (HKG: 2142) has announced receiving clinical trial approval from the US FDA for its bispecific antibody HBM7008. The drug, which targets the tumor antigen B7H4 and T cell co-stimulatory molecule 4-1BB, was first dosed in Phase I clinical trials in Australia in May and obtained clinical approval…
-
Joysbio Develops Rapid Test for SARS-CoV-2 Omicron Subvariants BA.4 and BA.5
•
China-based Joysbio (Tianjin) Biotechnology Co., Ltd. has developed a rapid test to diagnose the latest SARS-CoV-2 omicron subvariants BA.4 and BA.5. The Joysbio Coronavirus Antigen Rapid Test Kit, suitable for self-testing and requiring no professional support, can effectively detect these subvariants and has been certified by the Polish Centre for…
-
Antengene and BeiGene Collaborate on Selinexor and Tislelizumab Combination Trial for Lymphoma
•
China-based Antengene Corporation Ltd (HKG: 6996) has announced a clinical trial collaboration with BeiGene Inc. (Nasdaq: BGNE) to evaluate the combination of Antengene’s selinexor (trade name: Xpovio) with BeiGene’s anti-PD-1 drug tislelizumab (Baizean). The open-label, multi-center Phase I/II trial aims to explore this combination as a potential treatment for patients…
-
Sino Biopharmaceutical’s TQ-B3101 Accepted by NMPA for ROS1+ NSCLC Treatment
•
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the National Medical Products Administration (NMPA) has accepted the market filing for its Category 1 product TQ-B3101 for the treatment of ROS1-positive non-small cell lung cancer (NSCLC). Drug Mechanism and EfficacyTQ-B3101 is a small molecule inhibitor targeting tyrosine kinase ROS1/ALK/c-Met. It…
-
Sanyou Biopharmaceuticals and Dragon Sail Form Strategic Partnership for Global Biopharma Services
•
China-based Sanyou Biopharmaceuticals Co., Ltd has entered into a long-term strategic partnership with compatriot firm Dragon Sail Pharmaceutical. The collaboration aims to provide integrated and modular solutions covering biological drug research and development (R&D), Contract Development and Manufacturing Organization (CDMO) services, and commercial-scale production for the global biopharmaceutical industry. Partnership…
-
Westlake Therapeutics Secures RMB 100 Million in Series A+ Funding for Red Cell Therapy Pipeline
•
Hangzhou-based cell therapy firm Westlake Therapeutics, founded in 2019, has successfully raised over RMB 100 million (USD 14.95 million) in a Series A+ financing round. The funding was led by EFung Capital, with participation from Ao Peng Investment, Hangzhou Westlake Science Innovation Equity Investment, and Westlake Innovation (Hangzhou) Equity Investment.…
-
PhenoVision Bio Secures Angel Funding for Spatial Multi-Omics Technology Platform
•
Beijing-based PhenoVision Biotech, a one-stop spatial multi-omics solution provider, has reportedly secured “tens of millions” of renminbi in an angel financing round led exclusively by SIP Oriza Seed Fund. The proceeds will be dedicated to constructing a spatial multi-omics technology platform and advancing the development of clinical products. Funding and…
-
GSK Launches Nucala in China for Eosinophilic Granulomatosis with Polyangiitis
•
UK pharmaceutical giant GlaxoSmithKline (GSK, LON: GSK, NYSE: GSK) has announced the official market launch in China of its monoclonal antibody Nucala (mepolizumab) for the treatment of adult eosinophilic granulomatosis with polyangiitis (EGPA). This move expands the drug’s availability to patients in China, offering a new therapeutic option for this…
-
Genor Biopharma and Abogen Biosciences Collaborate on Cancer mRNA Therapies
•
China’s Genor Biopharma Co., Ltd (HKG: 6998) has entered into a co-development agreement with compatriot firm Abogen Biosciences Co., Ltd, a Suzhou-based mRNA drug developer. The collaboration aims to develop mRNA medicines against cancer by integrating Genor’s biologic antibody development platform with Abogen’s mRNA technology platform. Collaboration DetailsThe partnership combines…
-
Sunshine Guojian Pharmaceutical Signs Licensing Deal for Cipterbin ADC Development
•
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced the signing of a licensing agreement with compatriot firm Xiling Lab’s wholly-owned unit Chengdu Kelingyuan Pharmaceutical Co., Ltd. The agreement grants Chengdu Kelingyuan global development and commercialization rights to the anti-HER2 monoclonal antibody (mAb)…
-
Takeda Pharmaceutical’s Teduglutide Filed for Marketing Approval in China
•
The Center for Drug Evaluation (CDE) website in China indicates that Japan-based Takeda Pharmaceutical Co., Ltd’s best-in-class injectable therapy teduglutide has been filed for marketing approval. This marks a significant step for the drug in the Chinese market. Drug BackgroundTeduglutide, the first and only natural glucagon-like peptide-2 (GLP-2) drug approved…
